Roswell Park Comprehensive Cancer Center: Could Venetoclax Improve Outcomes of CAR T for Patients With Resistant B-Cell Lymphomas? New Insights at ASH
December 10, 2024
December 10, 2024
BUFFALO, New York, Dec. 10 (TNSres) -- The Roswell Park Comprehensive Cancer Center issued the following news release:
* * *
New work from Roswell Park adds evidence that FDA-approved leukemia drug improves T cell quality and function
Highlights
* Standard therapies prove ineffective for a third of patients with DLBCL
* Roswell Park team studying whether Bcl-2-inhibiting drug may enhance CAR T
* Underlying mechanism hi . . .
* * *
New work from Roswell Park adds evidence that FDA-approved leukemia drug improves T cell quality and function
Highlights
* Standard therapies prove ineffective for a third of patients with DLBCL
* Roswell Park team studying whether Bcl-2-inhibiting drug may enhance CAR T
* Underlying mechanism hi . . .